Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.
Mandatory CPR training in high school may contribute to higher rates of bystander intervention and improved survival following out-of-hospital cardiac arrest (OHCA), according to a registry study slated to be presented Nov. 11 at the American Heart Association’s Resuscitation Science Symposium in Chicago.
Medtronic data presented today reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.
Boston Scientific announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.
The American College of Cardiology, American Heart Association and Heart Rhythm Society on Nov. 6 released a new guideline for the evaluation and treatment of patients with bradycardia and cardiac conduction disorders.
Cannabis use is associated with double the risk of diabetic ketoacidosis among patients with type 1 diabetes, according to a research letter published Nov. 5 in JAMA Internal Medicine.
A 13-year study of type 2 diabetes patients has found metformin, one of the world’s highest-grossing anti-diabetic medications, could be protective against age-related macular degeneration, a leading cause of blindness in Americans older than 50.
Antibiotic prescriptions to prevent infective endocarditis (IE) decreased following a 2007 guideline update from the American Heart Association—even among high-risk patients for whom antibiotics were still recommended. Those patients showed an estimated 177 percent increase in IE incidence over the next several years, according to a new study.
Low-risk patients with mild hypertension derived no protective benefit from blood pressure drugs over 5.8 years of follow-up but had an increased risk of adverse effects potentially related to the medication, researchers reported in a new study.
The FDA has announced a Class I recall for 1.1 million packages of CoaguChek XS PT test strips used with point-of-care or in-home devices to adjust warfarin dosing.
